ILLUMINATE-B Phase 3 Results for OXLUMO® (lumasiran) Published in Pediatric Nephrology

ILLUMINATE-B Phase 3 Results for OXLUMO® (lumasiran) Published in Pediatric Nephrology

Results from the 12-month analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of OXLUMO® (lumasiran) in patients less than six years of age with primary hyperoxaluria type 1 (PH1) were published online in Pediatric Nephrology.

Read the paper in the Pediatric Nephrology



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.